Worldquant Millennium Advisors LLC Acquires 128,611 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Worldquant Millennium Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 167.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 205,529 shares of the medical research company’s stock after purchasing an additional 128,611 shares during the quarter. Thermo Fisher Scientific accounts for about 0.7% of Worldquant Millennium Advisors LLC’s holdings, making the stock its 27th largest holding. Worldquant Millennium Advisors LLC owned approximately 0.05% of Thermo Fisher Scientific worth $106,922,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Wedge Capital Management L L P NC raised its position in shares of Thermo Fisher Scientific by 4.1% in the 4th quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company’s stock worth $367,000 after acquiring an additional 28 shares in the last quarter. Annex Advisory Services LLC increased its position in Thermo Fisher Scientific by 7.7% during the 4th quarter. Annex Advisory Services LLC now owns 9,232 shares of the medical research company’s stock valued at $4,803,000 after buying an additional 660 shares in the last quarter. Gilman Hill Asset Management LLC increased its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Gilman Hill Asset Management LLC now owns 6,755 shares of the medical research company’s stock valued at $3,514,000 after buying an additional 273 shares in the last quarter. Diversify Wealth Management LLC increased its position in Thermo Fisher Scientific by 15.9% during the 4th quarter. Diversify Wealth Management LLC now owns 4,113 shares of the medical research company’s stock valued at $2,231,000 after buying an additional 564 shares in the last quarter. Finally, Mechanics Bank Trust Department increased its position in Thermo Fisher Scientific by 21.9% during the 4th quarter. Mechanics Bank Trust Department now owns 2,660 shares of the medical research company’s stock valued at $1,384,000 after buying an additional 477 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $413.75 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The stock’s fifty day moving average price is $451.89 and its 200-day moving average price is $508.88. The company has a market cap of $156.19 billion, a P/E ratio of 25.03, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period last year, the firm earned $5.11 EPS. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Raymond James reaffirmed an “outperform” rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Morgan Stanley increased their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Citigroup cut their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.